Oncimmune highlights the resurgence of Britain’s biotech sector
A resurgence in Britain’s small-cap biotech sector has been one of the few good things to come out of the coronavirus pandemic. As governments have hunted for vaccines, diagnostic tools and treatments, the speed and flexibility of the UK’s smaller biotech constituents has been increasingly recognised, funding for companies become more easily available and the … Read more
